Clinical trials: Adenoid Cystic Carcinoma
Recurrent Oral Cavity Adenoid Cystic Carcinoma, Recurrent Salivary Gland Carcinoma
Vorinostat in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma
This phase II trial studies how well vorinostat works in treating patients with adenoid cystic carcinoma that has come back (recurrent) or that has spread from where it started to nearby tissue or lymph nodes (locally advanced)…
- Conditions
- Recurrent Oral Cavity Adenoid Cystic Carcinoma, Recurrent Salivary Gland Carcinoma, Salivary Gland Adenoid Cystic Carcinoma, Stage III Major Salivary Gland Cancer AJCC v7
- Trial name
- NCT01175980
- Testing
- Laboratory Biomarker Analysis, Vorinostat
- Where
- 12 sites in United States, Canada
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma
MC200708 Pemetrexed and Pembrolizumab for the Treatment of Recurrent and/or Metastatic Salivary Gland Cancer
This phase II trial studies the effect of pemetrexed and pembrolizumab in treating patients with salivary gland cancer that has come back (recurrent) and/or has spread to other places in the body (metastatic).
- Conditions
- Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma, Stage IV Major Salivary Gland Cancer AJCC v8, Adenoid Cystic Carcinoma
- Trial name
- NCT04895735
- Testing
- Pembrolizumab, Pemetrexed Disodium, Biospecimen Collection
- Where
- 2 sites in United States
- Volunteers
- 45 people
- Sponsor
- Mayo Clinic
Metastatic Adenoid Cystic Carcinoma, Progressive Disease
Axitinib and Avelumab in Treating Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma
This phase II trial studies how well axitinib and avelumab work in treating patients with adenoid cystic carcinoma that has come back or spread to other places in the body.
- Conditions
- Metastatic Adenoid Cystic Carcinoma, Progressive Disease, Recurrent Adenoid Cystic Carcinoma
- Trial name
- NCT03990571
- Testing
- Avelumab, Axitinib
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- M.D. Anderson Cancer Center
Adenoid Cystic Carcinoma
Phase II Trial of Doxorubicin and Bortezomib in Patients With Incurable Adenoid Cystic Carcinoma of the Head and Neck
This is a Phase II trial non-randomized study to evaluate the objective response rate and stable disease rate (primary endpoints), progression-free survival, overall survival and toxicities with the combination of doxorubicin and…
- Trial name
- NCT00581360
- Testing
- doxorubicin and bortezomib
- Where
- 21 sites in United States
- Volunteers
- 10 people
- Sponsor
- University of Pittsburgh
Salivary Gland Cancer, Recurrent Salivary Gland Cancer
9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma
This trial is investigating an intravenous (IV) medication called 9-ING-41 in combination with chemotherapy (carboplatin) for the treatment of advanced salivary gland cancers.
- Conditions
- Salivary Gland Cancer, Recurrent Salivary Gland Cancer, Metastatic Cancer, Adenoid Cystic Carcinoma
- Trial name
- NCT05010629
- Testing
- 9-ING-41, Carboplatin, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- Robert Haddad, MD
Salivary Gland Cancer
Amivantamab in Adenoid Cystic Carcinoma
The purpose of the study is to determine if treatment with amivantamab will be efficacious in patients with recurrent and metastatic adenoid cystic carcinoma.
- Trial name
- NCT05074940
- Testing
- Amivantamab
- Where
- 5 sites in United States
- Volunteers
- 21 people
- Sponsor
- Trisha Wise-Draper
Adenoid Cystic Carcinoma
Axitinib (AG-013736) in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
The purpose of this study is to find out what effects, good and/or bad, a new treatment called axitinib has on the patient and adenoid cystic carcinoma. This type of cancer study is called a phase II study.
- Trial name
- NCT01558661
- Testing
- AG-013736 (AXITINIB)
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Head and Neck Cancer
Stereotactic Radiosurgery in Treating Patients With Locally Advanced or Recurrent Head and Neck Cancer
RATIONALE: Stereotactic radiosurgery may be able to send x-rays directly to the tumor and cause less damage to normal tissue. PURPOSE: This phase I trial is studying the side effects of stereotactic radiosurgery in treating…
- Trial name
- NCT00851253
- Testing
- stereotactic radiosurgery
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Boston Medical Center
Malignant Salivary Gland Neoplasm, Recurrent Salivary Gland Carcinoma
Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors
This phase II trial is studying how well dasatinib works in treating patients with malignant salivary gland tumors that have come back after treatment or have spread to other parts of the body.
- Conditions
- Malignant Salivary Gland Neoplasm, Recurrent Salivary Gland Carcinoma, Salivary Gland Adenoid Cystic Carcinoma, Stage IV Major Salivary Gland Cancer AJCC v7
- Trial name
- NCT00859937
- Testing
- Dasatinib, Laboratory Biomarker Analysis
- Where
- 34 sites in United States, Canada
- Volunteers
- 55 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Oral Cavity Adenoid Cystic Carcinoma, Recurrent Salivary Gland Carcinoma
Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma
This phase II trial studies how well Akt inhibitor MK2206 works in treating patients with progressive, recurrent, or metastatic adenoid cyst carcinoma (cancer).
- Conditions
- Recurrent Oral Cavity Adenoid Cystic Carcinoma, Recurrent Salivary Gland Carcinoma, Salivary Gland Adenoid Cystic Carcinoma, Stage IVA Major Salivary Gland Cancer AJCC v7
- Trial name
- NCT01604772
- Testing
- Akt Inhibitor MK2206, Laboratory Biomarker Analysis
- Where
- 51 sites in United States
- Volunteers
- 16 people
- Sponsor
- National Cancer Institute (NCI)
Head and Neck Cancer
Gemcitabine and Doxorubicin in Treating Patients With Recurrent or Progressive Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and doxorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00509665
- Testing
- doxorubicin hydrochloride, gemcitabine hydrochloride
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Medical University of South Carolina